Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures

Transfusion

Volumn 55, Issue 1, 2015, Pages 45-50

  Janbain, Maissaa ^a   Nugent, Diane J ^b   Powell, Jerry S ^c   St Louis, Jean ^d   Frame, Virginia B ^e   Leissinger, Cindy A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e CSL BEHRING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; AMMONIA; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13 CONCENTRATE; FRESH FROZEN PLASMA; HYPERTENSIVE FACTOR; INTERFERON; RIBAVIRIN; WARFARIN; ANTICOAGULANT AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AORTA STENOSIS; AORTA VALVE REPLACEMENT; APPENDECTOMY; ARTICLE; BALLOON PUMP; BILE DUCT CARCINOMA; BLEEDING; BLOOD CLOTTING FACTOR 13 DEFICIENCY; CARDIOPULMONARY BYPASS; CHOLECYSTECTOMY; CLINICAL ARTICLE; CRYOPRECIPITATE; DEFIBRILLATOR; DIPLOPIA; ELECTROCUTION; END STAGE RENAL DISEASE; EPISTAXIS; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMORRHOIDECTOMY; HEMOSTASIS; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTENSIVE CARE UNIT; INTERVERTEBRAL DISK HERNIA; ISCHEMIC COLITIS; LAMINECTOMY; LIVER RESECTION; MAJOR SURGERY; MALE; MENISCECTOMY; MIDDLE AGED; MINOR SURGERY; NONISCHEMIC CARDIOMYOPATHY; PARTIAL HEPATECTOMY; PATIENT HISTORY OF SURGERY; PEROPERATIVE CARE; PREOPERATIVE CARE; PROPHYLAXIS; RANGE OF MOTION; RESUSCITATION; SALPINGITIS; SPLENECTOMY; SURGICAL TECHNIQUE; TOOTH EXTRACTION; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; AGED; BLOOD LOSS, SURGICAL; CASE REPORT; COMPLICATION; FACTOR XIII DEFICIENCY; ORAL HEMORRHAGE; POSTOPERATIVE HEMORRHAGE; PROCEDURES; THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; BLOOD LOSS, SURGICAL; FACTOR XIII; FACTOR XIII DEFICIENCY; FEMALE; HUMANS; MALE; MIDDLE AGED; ORAL HEMORRHAGE; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; THROMBOSIS; WARFARIN;

EID: 84920872969     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12784     Document Type: Article

References (18)

1. Hsieh L, Nugent D,. Factor XIII deficiency. Haemophilia. 2008; 14: 1190-1200.
2. National Hemophilia Foundation. Factor XIII (fibrin stabilizing factor) deficiency. [cited 2014 May 19]. Available from: http://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders/Other-Factor-Deficiencies/Factor-XIII
3. Katona E, Penzes K, Molnar E, et al. Measurement of factor XIII activity in plasma. Clin Chem Lab Med 2011; 50: 1191-1202.
4. Jennings I, Kitchen S, Woods TA, et al. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost 2003; 1: 2603-2608.
5. Wettstein P, Haeberli A, Stutz M, et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 2004; 99: 1564-1569; table of contents.
6. Gerlach R, Tolle F, Raabe A, et al. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke 2002; 33: 1618-1623.
7. Lak M, Peyvandi F, Ali Sharifian A, et al. Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. J Thromb Haemost 2003; 1: 1852-1853.
8. Goldenberg NA, Manco-Johnson MJ,. Pediatric hemostasis and use of plasma components. Best Pract Res Clin Haematol 2006; 19: 143-155.
9. Todd T, Perry DJ,. A review of long-term prophylaxis in the rare inherited coagulation factor deficiencies. Haemophilia 2010; 16: 569-583.
10. ® (factor XIII concentrate [human]) [prescribing information]. Kankakee (IL): CSL Behring LLC; 2011.
11. Lusher J, Pipe SW, Alexander S, et al. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010; 16: 316-321.
12. ® P) for severe congenital factor XIII deficiency: a prospective multicentre study. J Thromb Haemost 2011; 9: 1264-1266.
13. ® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thromb Res 2012; 130 (Suppl 2): S12-14.
14. ® (catridecagog) [prescribing information]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc.; 2012.
15. Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93: 1101-1107.
16. Chandler WL, Patel MA, Gravelle L, et al. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001; 12: 101-108.
17. Mannucci PM, Duga S, Peyvandi F,. Recessively inherited coagulation disorders. Blood 2004; 104: 1243-1252.
18. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.